Related Experiment Videos
An additional marker for familial hypertrophic cardiomyopathy?
L Choudhury1, S al-Mahdawi, J French
1MRC Cyclotron Unit, Hammersmith Hospital, London, England.
Coronary Artery Disease
|June 1, 1993
Summary
Coronary flow reserve measurement using positron-emission tomography may help identify hypertrophic cardiomyopathy in equivocal family screening cases. This noninvasive method shows reduced flow in patients without clear diagnostic features or genetic mutations.
Area of Science:
- Cardiology
- Nuclear Medicine
- Genetics
Background:
- Family screening for hypertrophic cardiomyopathy (HCM) often yields equivocal cases.
- While MYH7 gene mutations are implicated, additional diagnostic tools are needed.
- Reduced coronary flow reserve (CFR) is observed in typical HCM, suggesting its potential utility in equivocal presentations.
Observation:
- Two subjects with family history of HCM were studied: one with a MYH7 mutation but no typical HCM features, and another with borderline left ventricular hypertrophy but no MYH7 mutation.
- Positron-emission tomography (PET) with oxygen-15 labeled water measured myocardial blood flow (MBF) at baseline and during pharmacologic vasodilation (dipyridamole).
- Coronary flow reserve was calculated as the ratio of hyperemic to baseline MBF.
Findings:
- Coronary flow reserve values were significantly reduced in both subjects (1.69 and 1.12) compared to normal controls (3.87 +/- 1.08).
- These findings suggest impaired coronary microvascular function despite differing clinical and genetic profiles.
Implications:
- Noninvasive CFR quantification by PET may aid in diagnosing HCM in patients with equivocal findings.
- Further research is warranted to validate CFR as a diagnostic biomarker for HCM.
- This technique could improve risk stratification and management in families with a history of HCM.